Información de Alnylam Pharmaceuticals Inc, dividendo de Alnylam Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Alnylam Pharmaceuticals Inc Compañía

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Información de la empresa

Código de la empresaALNY

Nombre de la empresaAlnylam Pharmaceuticals Inc

Fecha de salida a bolsaMay 28, 2004

Fundada en2003

Director ejecutivoDr. Yvonne L. Greenstreet, M.D.

Número de empleados2230

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 28

Dirección675 W Kendall St

CiudadCAMBRIDGE

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal02142-1168

Teléfono16175518200

Sitio Webhttps://www.alnylam.com/

Código de la empresaALNY

Fecha de salida a bolsaMay 28, 2004

Fundada en2003

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Phillip A. (Phil) Sharp, Ph.D.

Independent Director

266.90K

--

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

99.04K

+16.58%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.03K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

3.64K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

136.00

--

Ms. Colleen F. Reitan

Independent Director

--

Ms. Amy W. Schulman, J.D.

Independent Chairman of the Board

--

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Phillip A. (Phil) Sharp, Ph.D.

Independent Director

266.90K

--

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

99.04K

+16.58%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.03K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

3.64K

--

Desglose de ingresos

Divisa: USDHora de actualización: dom., 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

Por negocioUSD

Nombre

Ganancia

Proporción

AMVUTTRA

970.45M

43.16%

Regeneron Pharmaceuticals

302.80M

13.47%

GIVLAARI

255.87M

11.38%

ONPATTRO

252.86M

11.25%

OXLUMO

167.05M

7.43%

Other

299.22M

13.31%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

933.54M

41.52%

Europe

516.30M

22.96%

Net revenues from collaborations

510.22M

22.69%

Rest of World

196.39M

8.74%

Royalty revenue

91.79M

4.08%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

AMVUTTRA

970.45M

43.16%

Regeneron Pharmaceuticals

302.80M

13.47%

GIVLAARI

255.87M

11.38%

ONPATTRO

252.86M

11.25%

OXLUMO

167.05M

7.43%

Other

299.22M

13.31%

Accionista

Hora de actualización: vie., 21 de feb

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

Capital World Investors

12.76%

The Vanguard Group, Inc.

10.04%

Fidelity Management & Research Company LLC

9.95%

Capital Research Global Investors

5.36%

BlackRock Institutional Trust Company, N.A.

5.19%

Other

56.70%

Estadísticas de accionistas

Accionista

Proporción

Capital World Investors

12.76%

The Vanguard Group, Inc.

10.04%

Fidelity Management & Research Company LLC

9.95%

Capital Research Global Investors

5.36%

BlackRock Institutional Trust Company, N.A.

5.19%

Other

56.70%

Tipo

Accionista

Proporción

Investment Advisor

56.07%

Investment Advisor/Hedge Fund

32.20%

Corporation

3.44%

Hedge Fund

2.58%

Sovereign Wealth Fund

1.97%

Pension Fund

1.43%

Bank and Trust

1.19%

Research Firm

1.07%

Individual Investor

0.43%

Participación institucional

Hora de actualización: dom., 19 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

1235

131.13M

100.81%

-458.58K

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

2023Q1

1116

123.13M

99.37%

-5.56M

2022Q4

1103

122.98M

99.27%

-3.16M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Capital World Investors

16.60M

12.76%

+92.10K

+0.56%

Dec 31, 2024

The Vanguard Group, Inc.

13.06M

10.04%

+378.83K

+2.99%

Mar 31, 2025

Fidelity Management & Research Company LLC

12.94M

9.95%

-1.20M

-8.49%

Dec 31, 2024

Capital Research Global Investors

6.97M

5.36%

+1.72M

+32.89%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

6.75M

5.19%

+149.81K

+2.27%

Dec 31, 2024

Regeneron Pharmaceuticals Inc

4.44M

3.42%

+4.44M

--

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

4.38M

3.37%

+1.25M

+39.67%

Dec 31, 2024

Wellington Management Company, LLP

4.20M

3.23%

-756.72K

-15.28%

Dec 31, 2024

Baillie Gifford & Co.

4.04M

3.11%

-846.74K

-17.33%

Dec 31, 2024

Dodge & Cox

3.54M

2.72%

-82.27K

-2.27%

Dec 31, 2024

ETFs relacionados

Hora de actualización: dom., 6 de abr

Nombre

Proporción

Tema Neuroscience and Mental Health ETF

4.39%

VanEck Biotech ETF

4.19%

Global X Genomics & Biotechnology ETF

3.91%

ProShares Ultra Nasdaq Biotechnology

3.49%

First Trust NYSE Arca Biotechnology Index Fund

3.23%

iShares Biotechnology ETF

3.11%

Invesco Nasdaq Biotechnology ETF

3.05%

Franklin Genomic Advancements ETF

2.56%

American Century Focused Dynamic Growth ETF

2.52%

SPDR S&P Biotech ETF

2.5%

Tema Neuroscience and Mental Health ETF

Proporción4.39%

VanEck Biotech ETF

Proporción4.19%

Global X Genomics & Biotechnology ETF

Proporción3.91%

ProShares Ultra Nasdaq Biotechnology

Proporción3.49%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.23%

iShares Biotechnology ETF

Proporción3.11%

Invesco Nasdaq Biotechnology ETF

Proporción3.05%

Franklin Genomic Advancements ETF

Proporción2.56%

American Century Focused Dynamic Growth ETF

Proporción2.52%

SPDR S&P Biotech ETF

Proporción2.5%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Alnylam Pharmaceuticals Inc

251.560USD

Alnylam Pharmaceuticals Inc

251.560

Descripción general

Compañía